Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Dendritic cell-mediated immunization in macroglobulinemia.

Madhav V Dhodapkar1

  • 1Laboratory of Tumor Immunology and Immunotherapy, Rockefeller University, and Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA.

Seminars in Oncology
|April 30, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

MRD in multiple myeloma: Moving from "minimal" to "measurable".

Blood reviews·2026
Same author

Antigen-specific T-cell responses to SARS-CoV-2 vaccination after hematopoietic cell transplant or CAR T-cell therapy.

Blood advances·2026
Same author

Reading the "T" Leaves: Predicting Outcomes with Bispecific Antibodies in Multiple Myeloma.

Blood cancer discovery·2026
Same author

Rethinking Multiple Myeloma Treatment: The Biological and Clinical Insights Guiding Immune-Based Combinations.

Blood cancer discovery·2026
Same author

A single-cell atlas characterizes dysregulation of the bone marrow immune microenvironment associated with outcomes in multiple myeloma.

Nature cancer·2026
Same author

Linvoseltamab in Patients With Relapsed/Refractory Multiple Myeloma in the LINKER-MM1 Study: Longer Follow-Up and Subgroup Analyses.

Clinical lymphoma, myeloma & leukemia·2025

Generating dendritic cells (DCs) and loading them with tumor antigens offers new clinical strategies. Injecting antigen-loaded DCs can enhance antitumor immunity, potentially preventing disease progression in patients with macroglobulinemia.

Area of Science:

  • Immunology
  • Oncology
  • Vaccinology

Background:

  • Dendritic cells (DCs) are professional antigen-presenting cells (APCs) crucial for initiating immune responses and are key targets for vaccines.
  • Advances in laboratory generation and tumor antigen loading of DCs enable novel clinical applications.
  • DCs play a vital role in orchestrating adaptive immunity against tumors.

Purpose of the Study:

  • To explore the potential of antigen-loaded dendritic cells for cancer immunotherapy.
  • To investigate the use of autologous tumor antigens for DC-based vaccines.
  • To assess the efficacy of boosting antitumor immunity in patients with asymptomatic macroglobulinemia.

Main Methods:

  • Generation of large quantities of dendritic cells in vitro.

Related Experiment Videos

  • Loading of dendritic cells with tumor-associated antigens.
  • Clinical administration of antigen-loaded dendritic cells to patients.
  • Evaluation of immune responses and clinical outcomes.

    • Main Results:

    • Antigen-loaded DCs can be generated effectively for clinical use.
    • Injection of antigen-loaded DCs has the potential to enhance tumor-specific immunity.
    • Studies in myeloma suggest autologous tumor material is a promising antigen source.
    • Boosting antitumor immunity may help manage tumor progression.

    Conclusions:

    • Dendritic cell-based therapies represent a promising approach in cancer treatment.
    • The use of autologous tumor antigens enhances the specificity of DC vaccines.
    • Antigen-loaded DCs hold potential for preventing tumor progression, particularly in early-stage diseases like asymptomatic macroglobulinemia.